Creating an account and signing in will allow you to keep your Decision box results and view them later.
Provide some personal information and create a user account allowing to save your Decision box results and view them later.
Sign upCreating an account and signing in will allow you to keep your Decision box results and view them later.
For every 1,000 men who undergo screening, 1 death from prostate cancer is avoided thanks to screening (0.1 %).
Death is avoided for... | ||
---|---|---|
99.5% of men |
99.6% of men |
0.1% of men |
With | Without | Impact |
Design: Randomized multi-center trial; Participants: 162,243 men between the ages of 55 and 69 from 7 countries in Europe; Intervention: PSA screening, on average twice over a 13-year period (PSA cut-off level: 3-4 ng/mL).
For every 1,000 men, about 760 get a negative screening result. These men are initially reassured.
A sense of reassurance is felt by... | ||
---|---|---|
76% of men |
0% of men |
76% of men |
With | Without | Impact |
Design: Randomized multi-center trial; Participants: 162,243 men between the ages of 55 and 69 from 7 countries in Europe; Intervention: PSA screening, on average twice over a 13-year period (PSA cut-off level: 3-4 ng/mL).
For every 1,000 men who undergo screening, 100 have prostate cancer. Cancer is, on average, less severe in these men compared to men who have not been screened.
Getting an earlier treatment is possible for... | ||
---|---|---|
10% of men |
0% of men |
10% of men |
With | Without | Impact |
Schröder et al. [2014]. Lancet 384(9959):2027-2035.
Design: Randomized multi-center trial; Participants: 162,243 men between the ages of 55 and 69 from 7 countries in Europe; Intervention: PSA screening, on average twice over a 13-year period (PSA cut-off level: 3-4 ng/mL).
Of these 760 men identified as having a negative screening result, about 27 actually have prostate cancer. These men have been falsely reassured.
A false sense of reassurance is felt by... | ||
---|---|---|
27% of the 1,000 men who get screened |
0% of the 1,000 men who do not get sceeened |
27% of men |
With | Without | Impact |
Design: Randomized multi-center trial; Participants: 162,243 men between the ages of 55 and 69 from 7 countries in Europe; Intervention: PSA screening, on average twice over a 13-year period (PSA cut-off level: 3-4 ng/mL).
For every 1,000 men screened, about 240 require additional tests to confirm the presence of prostate cancer. Of these, for approximately 140 it will have been a false alarm as they do not actually have prostate cancer. These men will have experienced unnecessary anxiety.
Of these 140 men who received a false alarm, about 120 have an unnecessary biopsy. Of these:
Screening results in a false alarm for... | ||
---|---|---|
14% of men |
0% of men |
14% of men |
With | Without | Impact |
Devis: essai clinique à répartition aléatoire; Participants: 162 243 hommes âgés de 55 à 69 ans provenant de 7 pays européens; Intervention: Dépistage par le test de dosage de l'APS, en moyenne deux fois au cours d'un suivi de 13 ans (seuil d’APS utilisé : 3-4 ng/mL).
For every 1,000 men screened, about 100 receive a prostate cancer diagnosis after screening, and the majority will be treated.
Of the 100 men whose diagnosis is confirmed, about 40 would never have known they had cancer if they had not been diagnosed. Overdiagnosis is the discovery of cancer that would have never been detected without screening. This cancer would never have had an impact on the health or life of the person. If these men decide to undergo treatment, they could experience harmful effects of unnecessary treatments such as impotence or urinary incontinence.
Overdiagnosis occurs in... | ||
---|---|---|
4% of screened men |
0% of unscreened men |
4% of men |
With | Without | Impact |
Design: Randomized multi-center trial; Participants: 162,243 men between the ages of 55 and 69 from 7 countries in Europe; Intervention: PSA screening, on average twice over a 13-year period (PSA cut-off level: 3-4 ng/mL).
For every 1,000 men who choose not to get screened, about 932 do not have prostate cancer. These men will not have an unnecessary screening test or a biopsy to see if they really have cancer.
Design: Randomized multi-center trial; Participants: 162,243 men between the ages of 55 and 69 from 7 countries in Europe; Intervention: PSA screening, on average twice over a 13-year period (PSA cut-off level: 3-4 ng/mL).
Men who do not get screened avoid the anxiety and stress caused by waiting for screening and biopsy results.
Of every 1,000 men who choose not to get screened, about 40 avoid overdiagnosis as well as treatments and their possible complications.
Design: Randomized multi-center trial; Participants: 162,243 men between the ages of 55 and 69 from 7 countries in Europe; Intervention: PSA screening, on average twice over a 13-year period (PSA cut-off level: 3-4 ng/mL).
For every 1,000 men who choose not to get screened, 6 die of prostate cancer. Of these 6 men, 1 death by prostate cancer could have been avoided if the man had opted to get screened and treated.
Design: Randomized multi-center trial; Participants: 162,243 men between the ages of 55 and 69 from 7 countries in Europe; Intervention: PSA screening, on average twice over a 13-year period (PSA cut-off level: 3-4 ng/mL).
For every 1,000 men who choose not to get screened, 68 have cancer diagnosis after the onset of symptoms. On average, cancer is more severe in these men compared to men who have been screened.
Design: Randomized multi-center trial; Participants: 162,243 men between the ages of 55 and 69 from 7 countries in Europe; Intervention: PSA screening, on average twice over a 13-year period (PSA cut-off level: 3-4 ng/mL).
Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
This study presents a high risk of bias.